Opendata, web and dolomites

STOPFOP SIGNED

Saracatinib Trial tO Prevent FOP

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 STOPFOP project word cloud

Explore the words cloud of the STOPFOP project. It provides you a very rough idea of what is the project "STOPFOP" about.

activin    blocked    people    therapies    de    contractures    disabling    dsm    hypothesis    ensured    boards    50    active    regulatory    mice    activating    garmen    r206h    previously    fop    ossificans    soft    affordable    universities    repurposing    2a    patients    showed    establishing    label    safety    drug    congenital    rarity    syndrome    risking    centers    germany    saracatinib    unexplored    limb    azd0530    preserving    neofunction    shortening    progressiva    ideal    disease    efficacy    adults    exist    death    tissues    approved    london    solution    amsterdam    involvement    rare    engagement    investments    preclinical    randomized    receptor    5nm    bone    ectopic    12    potent    acvr1    clinical    expert    patient    morphogenetic    agencies    protein    roadmap    proof    advisory    performed    stakeholder    formed    teams    pricing    life    kinase    disability    progressive    partenkirchen    once    historical    fibrodysplasia    data    mutations    mediated    16    expectations    regulation    oxford    stimulation    netherlands    harvard    option    indication    extension    alk2    inhibitor    placebo    uk    assets    reduce    treatment    astrazeneca    movement   

Project "STOPFOP" data sheet

The following table provides information about the project.

Coordinator
STICHTING VUMC 

Organization address
address: DE BOELELAAN 1117
city: AMSTERDAM
postcode: 1081 HV
website: www.vumc.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 1˙999˙712 €
 EC max contribution 999˙710 € (50%)
 Programme 1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
 Code Call H2020-JTI-IMI2-2017-13-two-stage
 Funding Scheme IMI2-RIA
 Starting year 2019
 Duration (year-month-day) from 2019-05-01   to  2022-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    STICHTING VUMC NL (AMSTERDAM) coordinator 525˙756.00
2    THE ROYAL NATIONAL ORTHOPAEDIC HOSPITAL NATIONAL HEALTH SERVICE TRUST UK (STANMORE) participant 253˙559.00
3    KLINIKUM GARMISCH-PARTENKIRCHEN GMBH DE (GARMISCH PARTENKIRCHEN) participant 216˙645.00
4    THE BRIGHAM AND WOMEN'S HOSPITAL INC US (BOSTON MA) participant 1˙875.00
5    THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD UK (OXFORD) participant 1˙875.00
6    ASTRAZENECA AB SE (SODERTAELJE) participant 0.00

Map

 Project objective

Fibrodysplasia ossificans progressiva (FOP) is a rare, disabling and life-shortening congenital syndrome for which no effective therapies exist. Repurposing of AZD0530 (saracatinib, AstraZeneca) would be an ideal solution for de-risking early clinical studies. Using existing assets and investments, this may allow more affordable pricing once an indication is approved. Ectopic bone is formed in soft tissues due to activating mutations in the bone morphogenetic protein receptor kinase ALK2/ACVR1, leading to progressive contractures and early death. Preclinical studies showed AZD0530, previously unexplored in FOP, to be a potent (5nM) inhibitor of ALK2 kinase and ALK2-R206H-mediated neofunction after activin stimulation. In mice, AZD0530 blocked ectopic bone formation preserving limb movement.

Hypothesis: AZD0530 will reduce ectopic bone formation and progressive disability in people with FOP.

AIM: to provide proof of concept that AZD0530 is an effective drug in the treatment of patients with FOP.

Methods: Based on the rarity of the disease and expected drug efficacy (50% reduction in new bone), a phase 2A proof of concept study including a 6 month randomized placebo controlled study and 12 month open label extension study using historical data, is proposed including 16 adults with active FOP disease. The study will be performed in three European FOP expert Centers (Amsterdam The Netherlands – Lead, London UK, and Garmen Partenkirchen Germany). The study will be performed in collaboration with the expert preclinical teams at the Universities of Oxford and Harvard. FOP expert and patient engagement as well as safety will be ensured by establishing advisory, DSM and stakeholder boards. Early involvement of the regulatory agencies are planned.

Expectations: we will develop a roadmap for further studies and regulation of this new treatment option in FOP based on the results.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "STOPFOP" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "STOPFOP" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.7.)

GNA NOW (2019)

NOVEL GRAM-NEGATIVE ANTIBIOTIC NOW

Read More  

EBOVAC3 (2018)

Bringing a prophylactic Ebola vaccine to licensure

Read More  

AB-DiRecT (2019)

Antibiotic Distribution and Recovery in Tissue

Read More